H. Lundbeck A/S

This study tested whether adding eptinezumab to a brief educational program helps adults with both migraine and medication overuse headache. Over 600 participants received either eptinezumab or a placebo. The goal was to see if the drug could reduce the number of migraine days an…

This study looked at the long-term safety of eptinezumab, a drug given by IV infusion to prevent migraines. It included 160 Japanese patients who had already completed a previous study. The main goal was to see if the drug is safe and tolerable over 60 weeks of treatment.

This clinical trial tested a new drug called Lu AG09222 to prevent migraines in 874 adults who had already tried 1 to 4 other preventive medications without success. The study compared different doses of the drug against a placebo to find the best dose. The main goal was to see i…

This study tested a drug called eptinezumab to see if it can prevent migraines in people with chronic migraine (15 or more headache days per month). About 981 adults took part, receiving either the drug or a placebo. The main goal was to see if the drug reduced the number of mont…

This study tests whether eptinezumab can reduce migraine days and improve quality of life in 164 adults who previously did not get enough relief from other CGRP-targeting migraine drugs. Participants receive the drug and report changes in migraine frequency and severity over time…

This early study tested a new drug called Lu AF28996 in 57 people with Parkinson's disease. The main goal was to see if the drug is safe and how the body handles it. Researchers measured side effects and drug levels in the blood. This is a first step to see if the drug might help…

This early-stage study looked at whether it is safe to take the experimental drug Lu AG09222 together with the approved migraine pill ubrogepant. 43 adults with migraine received both treatments or a placebo injection. The main goal was to track any side effects, not to measure h…